Alcohol Septal Ablation and Pacemaker Implantation: Results After 5 Years

Alcohol septal ablation is used to treat patients with obstructive hypertrophic cardiomyopathy. A significant complication in this intervention is atrioventricular block requiring pacemaker implantation in 7% to 20% of cases. Current evidence is limited for clinical results at follow-up for these patients.

Ablación septal con alcohol e implante de marcapasos

The aim of this study was to evaluate the results for patients with permanent pacemaker implantation related to high-degree atrioventricular block.

The EURO-ASA multinational registry was used. A total of 1814 patients with 5 years of follow-up were analyzed. Within 30 days after ablation, 9.4% (170 patients) had a pacemaker implanted. 

After, propensity score matching was conducted to homogenize groups, and 278 patients were compared (139 pacemaker arm vs. 139 non-pacemaker arm). There were no long-term differences in terms of functional class and survival. 

However, patients in the pacemaker arm presented a lower long-term left ventricular (LV) outflow tract gradient (p < 0.01), a more pronounced decrease in LV gradient (p < 0.01), lower ejection fraction (= 0.02), and lower rates of reintervention (ablation or surgery) (p = 0.02).

Read also: Prognosis After Pacemaker Implantation in Alcohol Septal Ablation.

In multivariate analysis, older age (p < 0.01) and branch block prior to ablation (p = 0.01) were predictors of all-cause mortality.

Conclusion

Patients with hypertrophic cardiomyopathy treated with alcohol septal ablation had about a 9-% likelihood of pacemaker implantation within 30 days of the procedure. In the long term, patients who underwent pacemaker implantation had lower LV outflow tract gradient, greater steep decline in LV outflow tract gradient, lower ejection fraction, and lower rates of reintervention. However, they had similar survival rates and functional class compared with patients who did not undergo pacemaker implantation.

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes of Patients With Hypertrophic Obstructive Cardiomyopathy and Pacemaker Implanted After Alcohol Septal Ablation.

Reference: Josef Veselka, MD et al J Am Coll Cardiol Intv 2022;15:1910–1917.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...